Aurobindo Pharma Limited

1,249

INR
-0.45(-0.04%)
As of November 14, 2024 10:00:00 AM

Aurobindo Pharma Limited Share Price Information

24 hour Low and High

Low: 1243.15
High: 1271.3

All time High

1569.40

Price Change 1h

+₹-19.10 +-1.51%

Price Change 1d

+₹-19.10 +-1.51%

Price Change 1w

+₹-101.60 +-7.52%

Aurobindo Pharma Limited Market Information

Exchange

NSE

Market Cap

81611.39 Cr

About Aurobindo Pharma Limited Share

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

26015

CEO

Dr. Makkapati Satakarni B.E., M.B.A., Ph.D.

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • Bharat Electronics, Auro Pharma, UBL & Taj GVK Hotels: Top 4 stock picks by SMC Global
  • Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts
  • Aurobindo Pharma : PR Q2 FY 2024 25
  • Aurobindo Pharma Shares Hit Record Ahead Of Buyback Decision
  • Aurobindo Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024

FAQs

Aurobindo Pharma Limited

1,249

INR
-0.45(-0.04%)
As of November 14, 2024 10:00:00 AM

Aurobindo Pharma Limited Share Price Information

24 hour Low and High

Low: 1243.15
High: 1271.3

All time High

1569.40

Price Change 1h

+₹-19.10 +-1.51%

Price Change 1d

+₹-19.10 +-1.51%

Price Change 1w

+₹-101.60 +-7.52%

Aurobindo Pharma Limited Market Information

Exchange

NSE

Market Cap

81611.39 Cr

About Aurobindo Pharma Limited Share

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

26015

CEO

Dr. Makkapati Satakarni B.E., M.B.A., Ph.D.

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • Bharat Electronics, Auro Pharma, UBL & Taj GVK Hotels: Top 4 stock picks by SMC Global
  • Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts
  • Aurobindo Pharma : PR Q2 FY 2024 25
  • Aurobindo Pharma Shares Hit Record Ahead Of Buyback Decision
  • Aurobindo Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024

FAQs